CN101152195A - Application of aminoglycoside antibiotic in preparing pharmaceutical composition for treating drug-fast bacteria infection - Google Patents

Application of aminoglycoside antibiotic in preparing pharmaceutical composition for treating drug-fast bacteria infection Download PDF

Info

Publication number
CN101152195A
CN101152195A CNA2007101328564A CN200710132856A CN101152195A CN 101152195 A CN101152195 A CN 101152195A CN A2007101328564 A CNA2007101328564 A CN A2007101328564A CN 200710132856 A CN200710132856 A CN 200710132856A CN 101152195 A CN101152195 A CN 101152195A
Authority
CN
China
Prior art keywords
application
pharmaceutical composition
preparation
aminoglycoside antibiotics
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2007101328564A
Other languages
Chinese (zh)
Other versions
CN101152195B (en
Inventor
刘军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fangyuan Pharmaceutical Co., Ltd., Changzhou
Original Assignee
WUXI SUKE BIOLOGICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WUXI SUKE BIOLOGICAL TECHNOLOGY Co Ltd filed Critical WUXI SUKE BIOLOGICAL TECHNOLOGY Co Ltd
Priority to CN2007101328564A priority Critical patent/CN101152195B/en
Publication of CN101152195A publication Critical patent/CN101152195A/en
Priority to PCT/CN2008/001677 priority patent/WO2009049490A1/en
Application granted granted Critical
Publication of CN101152195B publication Critical patent/CN101152195B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention provies an application of an aminoglycoside antibiotic in preparing drug combination to treat drug-resistant bacteria infection, belonging to the aminoglycoside antibiotic application technical field. The invention provides the application method of 2'-NH<SUB>2</SUB>-3',4'-dideoxy aminoglycoside antibiotic1-N-acyl derivatives and the preparation methods of the derivatives and agents of the product.

Description

The application of a kind of aminoglycoside antibiotics in the Pharmaceutical composition of preparation treatment drug-fast bacteria infection
Technical field
The application of a kind of aminoglycoside antibiotics in the Pharmaceutical composition of preparation treatment drug-fast bacteria infection belongs to the aminoglycoside antibiotics applied technical field.The present invention relates to have 2 '-NH 2-3 ', the 1-N-acylated derivatives and the application in preparation antimicrobial agent Pharmaceutical composition thereof of the aminoglycoside antibiotics of 4 '-two deoxidation structures.
Background technology
Document 1CN1420120A,
Document 2ZL93112412.3,
Document 3ZL01133701.X,
Document 4USP4117221,
Document 5USP4230847,
Document 6USP5442047.
Since the aminoglycoside antibiotics listing, its broad spectrum antibiotic activity is especially to the show strong antibacterial action of gram negative bacteria, to have good synergism and their main ears, nephrotoxicity to have predictable with widely used beta-lactam antibiotic clinically, thereby becomes an indispensable clinically class antibiotic.
In order to reduce toxicity and enhancing to the activity of fastbacteria, also developed some semi-synthetic aminoglycoside antibioticss, as arbekacin, isepamicin, etimicin, netilmicin, their structural formula is as follows:
AHB=(s)-4-amino-2-maloyl group,
AHP=(s)-3-amino-2-hydroxyl propiono,
Arbekacin (1-N-AHB-dibekacin):
Figure A20071013285600051
Isepamicin (1-N-AHP-Gentamicin B):
Figure A20071013285600061
Etimicin (1-N-ethyl Gentamicin C1a):
Figure A20071013285600062
Netilmicin (1-N-Netilmicin):
Figure A20071013285600063
In recent years, along with being extensive use of of all kinds of antibacterials, induce many Resistant strains, cause producing many clinicians of order and be difficult to the effectively infection disease of treatment, especially the coagulase negative staphylococcus (MRCNS) etc. that various antibacterial is shown height, multidrug resistant methicillin-resistant staphylococcus aureus (MRSA), methicillin resistance becomes and infects the very big obstacle of disease in treating clinically.
The semi-synthetic aminoglycoside antibiotics of above-mentioned exploitation, except arbekacin has the clear and definite effect MRSA, all the other products are all undesirable to the antibacterial effect of MRSA.
Disclose acyl derivatives such as many 1-N-gentamycins and sisomicin in the document 4, reported that also these acylated derivatives have good antibacterial activity to fastbacteria, can make the antibiotic formulations of commercial usefulness.But document and unexposed these derivants are to the antibacterial activity of MRSA and MRCNS equal altitudes fastbacteria, and not all chemical compound all has good antibacterial activity to MRSA in the disclosed derivant of document, and for example 1-N-AHP Gentamicin B (isepamicin) does not just have good antibacterial activity to MRSA.Therefore, above-mentioned patent documentation can not cover the inventive concept of this patent.
Document 5 discloses employing bivalent metal ion complex protection, the synthetic 1-NH that removes 2The position is the protection intermediate of free state, further carries out the method for specificity derivatization in the 1-N position, and document 6 discloses uses the zinc ion complexation, formoxyl protection intermediate, the new method of synthetic isepamicin.But do not cover synthetic method of the present invention.
Summary of the invention
The purpose of this invention is to provide the application of a kind of aminoglycoside antibiotics as preparation treatment drug-fast bacteria infection medicine, the problem that solve is to provide has powerful antibiotic and aminoglycoside antibiotics that production cost is low to MRSA and MRCNS.
In order to address this problem, the inventor has carefully compared the antibacterial activity of the aminoglycoside antibiotics with different structure feature of clinical practice to clinical isolating pathogen.Wherein,
The architectural feature of etimicin: the 1-N-ethyl, 2 '-NH 2, 3 ', 4 '-two deoxidations, 3 " N-CH 3,
The architectural feature of isepamicin: 1-N-AHP, 2 '-hydroxyl, 3 ', 4 '-dihydroxy, 3 " N-CH 3,
The architectural feature of amikacin: 1-N-AHB, 2 '-hydroxyl, 3 ', 4 '-dihydroxy, 3 " NH 2,
The architectural feature of arbekacin: 1-N-AHB, 2 '-NH 2, 3 ', 4 '-two deoxidations, 3 " NH 2,
The architectural feature of netilmicin: the 1-N-ethyl, 2 '-NH 2, 3 ', 4 '-two deoxidations, 3 " N-CH 3, 4 '=5 ' double bond structure,
SK-701=1-N-(S)-3-amino-2-hydroxyl propionyl Gentamicin C1a;
SK-702=1-N-(S)-3-amino-2-hydroxyl propiono-3 " N-demethylation Gentamicin C1a.
The architectural feature of SK-701: 1-N-AHP, 2 '-NH 2, 3 ', 4 '-two deoxidations, 3 " N-CH 3,
The architectural feature of SK-702: 1-N-AHP, 2 '-NH 2, 3 ', 4 '-two deoxidations, 3 " NH 2
The antibiotic of the various different structure features of table 1. is to the antibacterial activity of MRSA and MRCNS
Antibiotic MRSA MRCNS
MIC 50 (mg/L) MIC 90 (mg/L) MIC 50 (mg/L) MIC 90 (mg/L)
SK-701 0.5 1 0.06 0.125
SK-702 8 32 2 4
Etimicin ＞128 ＞128 16 128
Isepamicin 64 128 4 16
Amikacin ＞128 ＞128 8 64
Netilmicin (document 1) 16 64
By comparing, can see:
1.4 '=5 ' double bond structure (netilmicin) be not the necessary structure that antibiotic has anti-MRSA;
2.1-N acidylate (amikacin, isepamicin) neither have the unique necessary structure of anti-MRSA by antibiotic;
3.1-N the anti-MRSA effect of alkylating product (netilmicin, etimicin) is little.
Thus, we be surprised to find with have 2 '-NH 2-3 ', the antibiotic of 4 '-two deoxidation architectural features is that the synthetic 1-N acyl derivative of precursor has significant anti-MRSA and MRCNS activity, thereby finished the present invention.
The invention provides have 2 '-NH 2-3 ', the aminoglycoside antibiotics 1-N-acyl derivative of 4 ' two deoxidation architectural features is as the application of preparation treatment drug-fast bacteria infection pharmaceutical formulation.
Technical scheme of the present invention: the application of-kind of aminoglycoside antibiotics in the Pharmaceutical composition of preparation treatment drug-fast bacteria infection, this aminoglycoside antibiotics has following 1-N acylated derivatives structure
Figure A20071013285600081
R=CH 3CO, (S)-CH 2(NH 2) CH (OH) CO, or (S)-CH 2(NH 2) CH 2CH (OH) CO,
R 1=H or CH 3, R 2=H or CH 3
This aminoglycoside antibiotics is R=(S)-CH 2(NH 2) CH (OH) CO, R 1=H, R 2=CH 3, structure is as follows:
Figure A20071013285600082
Be the application of 1-N-(s)-3-amino-2-hydroxyl propionyl Gentamicin C1a in the Pharmaceutical composition of preparation treatment drug-fast bacteria infection.Or this aminoglycoside antibiotics is R=(S)-CH 2(NH 2) CH (OH) CO, R 1=R 2=H, structure is as follows:
Figure A20071013285600083
" the application of N-demethylation Gentamicin C1a in the Pharmaceutical composition of preparation treatment drug-fast bacteria infection that be 1-N-(s)-3-amino-2-hydroxyl propionyl-3.
Described fastbacteria is a methicillin-resistant staphylococcus aureus, or fastbacteria is the methicillin-resistant coagulase negative staphylococcus.
Described Pharmaceutical composition; by forming, and be 0.01%～99.99% to be that 99.99%～0.01% weight proportion is formed with containing medicinal carrier by this 1-N acylated derivatives or its pharmaceutical salts as this 1-N acylated derivatives of active component or its pharmaceutical salts and pharmaceutical carrier.
The preparation method of described Pharmaceutical composition is that the 1-N acylated derivatives of effective dose or its pharmaceutical salts is mixed mutually with pharmaceutical carrier, makes through the packing of routine, sterilization.
Described Pharmaceutical composition is tablet, aqueous injection, injectable powder, collyrium, aerosol, cream or aerosol agent.
The preparation method of the aminoglycoside antibiotics chemical compound of following structure
Figure A20071013285600091
R=CH 3CO, (S)-CH 2(NH 2) CH (OH) CO, or (S)-CH 2(NH 2) CH 2CH (OH) CO
R 1=H or CH 3,
Comprise the steps:
1) carrying out formylation reaction after making parent nucleus compound 1 bit amino be complex state with bivalent metal ion, is zinc ion, cobalt ion or nickel ion as the bivalent metal ion of complexation;
2) remove metal ion;
3) carry out R base derivative reaction in the 1-N position;
4) specificity is removed the formylated protecting group;
5) target product is carried out purification, product purification adopts the cation exchange resin column chromatography method, carries out eluting with the ammonia spirit of variable concentrations; Or product purification employing adsorbent resin column chromatography method, carry out eluting with Different concentrations of alcohol, methanol or aqueous acetone solution.
The preparation method of the aminoglycoside antibiotics chemical compound of following structure
Figure A20071013285600101
R=CH 3CO, (S)-CH 2(NH 2) CH (OH) CO, or (S)-CH 2(NH 2) CH 2CH (OH) CO,
R 1=H or CH 3,
Comprise the steps:
1) parent nucleus compound is realized 3 " obtaining 3 after the N demethylating reaction is also purified "-N-demethylation products with iodine or iodide;
2) carrying out formylation reaction after making 1 bit amino be complex state with bivalent metal ion, is zinc ion, cobalt ion or nickel ion as the bivalent metal ion of complexation;
3) remove metal ion;
4) carry out R base derivative reaction in the 1-N position;
5) specificity is removed the formylated protecting group;
6) target product is carried out purification, product purification adopts the cation exchange resin column chromatography method, carries out eluting with the ammonia spirit of variable concentrations; Or product purification employing adsorbent resin column chromatography method, carry out eluting with Different concentrations of alcohol, methanol or aqueous acetone solution.
Beneficial effect of the present invention:
Arbekacin has same architectural feature, and significant anti-MRSA activity is also arranged.But arbekacin is a kanamycin class aminoglycoside antibiotics, and its adopt complicated chemical method carry out 3 ', the two deoxidations of 4-, synthetic route is long, complex process, cost height.
For realizing the present invention cost-effectively, the present invention with natural origin, economy be easy to get have 2 '-NH 2-3 ', the antibiotic of 4 '-two deoxidation architectural features is as the synthetic 1-N-acylated derivatives of raw material, make the present invention have good industrial applications and be worth.
The present invention selects natural origin has 2 '-NH 2-3 ', the Gentamicin C1a of 4-two deoxidation architectural features is that the synthetic 1-N-acylated derivatives of raw material is:
SK-701=1-N-(S)-3-amino-2-hydroxyl propionyl Gentamicin C1a;
SK-702=1-N-(S)-3-amino-2-hydroxyl propiono-3 " N-demethylation Gentamicin C1a.
But be not limited only to this, 1-N-(S)-4-amino-2-maloyl group radical derivative and 1-N-acetyl derivative also can adopt method provided by the invention to synthesize.
The structure determination data of SK-701 and SK-702 are as follows:
1.MS:SK-701 M+1=537, its molecular weight are 536
SK-702, M+1=523, its molecular weight are 522
2. 13The C-NMR measurement result sees Table 2.
Table 2
SK-701 SK-702
C No. δppm C No. δppm
1 177.07 1 177.6
1′ 103.8 1′ 103.8
1″ 101.5 1″ 101.5
4 88.9 4 88.9
6 82.2 6 82.3
5 77.6 5 77.7
2 75.1 2 75.3
4″ 75.1 4″ 74.3
5′ 73.1 5′ 73.1
2″ 71.2 2″ 72.3
5″ 70.4 5″ 70.5
3″ 65.9 3″ 57.3
1 52.6 1 52.6
2′ 52.3 2′ 50.2
3 51.9 3 51.9
3 47.6 3 47.7
6′ 46.5 6′ 46.6
3″-N-CH 3 39.7
2 37.3 2 37.3
3′ 30.2 3′ 30.2
4′ 28.6 4′ 28.6
4″-C-CH 3 24.3 4″-C-CH 3 23.8
3. 1The H-NMR characteristic sees Table 3
Table 3
SK-701 SK-702
δ5.20 1H d 1′ δ5.20 1H d 1′
δ5.10 1H d 1″ δ5.12 1H d 1″
δ4.18 1H t 2 δ4.19 1H t 2
δ2.50 3H s 3″-N-CH 3
δ1.21 3H s 4″-C-CH 3 δ1.18 3H s 4″-C-CH 3
Disclosed by the inventionly have 2 '-NH 2-3 ', the aminoglycoside antibiotics 1-N-acyl derivative of 4 '-two deoxidation architectural features not only demonstrates that MRSA and MRCNS are had the excellent antibiotic effect, but also demonstrate gram negative bacteria is also had good antibacterial action.
The drug sensitive detection method of antibacterial: press the double dilution method of agar that CLSI (Clinical and Laboratory Standards Institute) recommends, carry out the mensuration of sample to the minimum inhibitory concentration (MIC) of clinical isolates.Antibacterials concentration is 12 double dilution factors of concentration of 128mg/L-0.06mg/L.Bacterial load is 10 4The CFU/ point.The Quality Control bacterial strain is: the susceptibility criterion of golden yellow Fructus Vitis viniferae ball ATCC29213 (MSSA), escherichia coli ATCC25922, the false unit cell ATCC27853. of Aerugo amikacin is pressed CLSI2007 version standard.The outstanding table of result of the test 4-8.
Table 4SK-701, investigational agents such as SK-702 are to the susceptibility (MICmg/L) of aerobic gram-positive cocci
Antibacterial (strain number) Antibacterials The MIC scope MIC 50 MIC 90
MRSA (50) MSSA (20) MRCNS (50) SK-701 SK-702 etimicin isepamicin amikacin SK-701 SK-702 etimicin isepamicin amikacin SK-701 SK-702 etimicin isepamicin amikacin 0.125-1 0.125-64 0.125-＞128 1-＞128 1-＞128 0.06-0.25 0.06-0.5 0.06-4 1-8 1-4 0.06-0.25 0.06-4 0.06-128 0.5-32 0.5-128 0.5 8 ＞128 64 ＞128 0.25 0.25 0.25 2 2 0.06 2 16 4 8 1 32 ＞128 128 ＞128 0.25 0.5 0.5 4 4 0.125 4 128 16 64
MSCNS (20) SK-701 SK-702 etimicin isepamicin amikacin 0.06-0.125 0.06-4 0.06-64 0.5-8 0.5-16 0.06 0.125 0.125 1 1 0.125 1 8 2 4
Table 5SK-701, investigational agents such as SK-702 are to the susceptibility (MICmg/L) of aerobic gram negative bacilli
Antibacterial (strain number) Antibacterials The MIC scope MIC 50 MIC 90
Escherichia coli (50) Klebsiella Pneumoniae (50) enterobacter cloacae (20) serratia marcesens (20) Pseudomonas aeruginosa (20) SK-701 SK-702 Etimicin Isepamicin amikacin SK-701 SK-702 Etimicin Isepamicin amikacin SK-701 SK-702 Etimicin Isepamicin amikacin SK-701 SK-702 Etimicin Isepamicin amikacin SK-701 SK-702 Etimicin Isepamicin amikacin 0.125-＞128 0.5-＞128 0.25-＞128 0.125-＞128 0.5-＞128 0.125-＞128 0.25-＞128 0.25-＞128 0.25-＞128 0.5-＞128 0.25-＞128 0.25-＞128 0.25-＞128 0.5-＞128 1-＞128 0.5-＞128 1-＞128 0.5-＞128 1-＞128 2-＞128 0.5-＞128 0.06-＞128 0.125-＞128 0.5-＞128 0.5-＞128 0.25 0.5 2 0.5 1 0.25 0.5 0.5 0.5 1 1 4 32 1 8 1 2 2 2 4 2 1 4 4 4 0.5 1 32 1 4 ＞128 ＞128 ＞128 ＞128 ＞128 4 4 64 2 16 ＞128 ＞128 ＞128 ＞128 ＞128 8 4 16 32 32
Investigational agents such as table 6-1SK-701 and SK-702 are to the accumulative total bacteriostasis rate (%) to clinical isolates 300 strains
Antibacterial (strain number) Medicine MIC(mg/L)
0.5 1 2 4 8
MRSA (50) MSSA (20) MRCNS (50) MSCNS (20) escherichia coli (50) Klebsiella Pneumoniae (50) SK-701 SK-702 Etimicin Isepamicin amikacin SK-701 SK-702 Etimicin Isepamicin amikacin SK-701 SK-702 Etimicin Isepamicin amikacin SK-701 SK-702 Etimicin Isepamicin amikacin SK-701 SK-702 Etimicin Isepamicin amikacin SK-701 SK-702 Etimicin Isepamicin amikacin 86 6 6 0 0 100 100 90 0 0 100 22 8 4 4 100 85 75 20 25 92 54 46 84 4 70 70 66 70 10 100 8 6 2 2 100 100 90 15 15 100 40 8 16 8 100 95 75 60 65 96 90 48 94 58 70 70 66 70 66 100 20 6 2 2 100 100 95 75 65 100 84 16 18 16 100 95 85 95 85 98 92 50 98 88 70 72 66 70 70 100 38 8 4 4 100 100 100 95 100 100 100 22 56 40 100 100 85 95 95 98 94 50 98 90 72 72 66 70 70 100 58 8 8 4 100 100 100 100 100 100 100 28 74 70 100 100 95 100 95 98 98 58 98 94 72 72 66 70 70
Investigational agents such as table 6-2SK-701 and SK-702 are to the accumulative total bacteriostasis rate (%) to clinical isolates 300 strains
Antibacterial (strain number) Medicine MIC(mg/L)
0.5 1 2 4 8
Enterobacter cloacae (20) serratia marcesens (20) Pseudomonas aeruginosa (20) SK-701 SK-702 etimicin isepamicin amikacin SK-701 SK-702 etimicin isepamicin amikacin SK-701 SK-702 etimicin isepamicin amikacin 45 45 40 10 0 20 0 10 0 0 10 15 5 5 5 50 45 45 55 30 50 40 35 10 0 25 55 5 5 10 85 45 45 90 45 65 75 75 60 25 50 70 25 30 40 90 90 45 90 45 80 75 75 80 75 75 90 55 55 55 95 95 45 90 80 80 80 75 80 75 90 90 75 75 80
Investigational agents such as table 7.SK-701 and SK-702 are to distributing to MRSA 50 strain MIC and accumulation bacteriostasis rate (%)
Antimicrobial drug MIC(mg/L)
≤0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 ＞128
SK701 Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 3 3 6.0 19 22 44.0 21 43 86.0 7 50 100.0
SK702 Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 2 2 4.0 1 3 6.0 1 4 8.0 6 10 20.0 9 19 38.0 10 29 58.0 15 44 88.0 5 49 98.0 1 50 100.0
Etimicin Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 1 1 2.0 2 3 6.0 1 4 8.0 1 5 10.0 7 12 24.0 2 14 28.0 8 22 44.0 28 50 100.0
Isepamicin Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 1 1 2.0 1 2 4.0 2 4 8.0 5 9 18.0 11 20 40.0 8 28 56.0 18 46 92.0 4 50 100.0
Amikacin Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 1 1 2.0 1 2 4.0 1 3 6.0 2 5 10.0 5 10 20.0 9 19 38.0 31 50 100.0
Investigational agents such as table 8.SK-701 and SK-702 are to distributing to MRCNS 50 strain MIC and accumulation bacteriostasis rate (%)
Antimicrobial drug MIC(mg/L)
≤0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 ＞128
SK701 Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 28 28 56.0 18 46 92.0 4 50 100.0
SK702 Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 3 3 6.0 1 4 8.0 6 10 20.0 1 11 22.0 9 20 40.0 22 42 84.0 8 50 100.0
Etimicin Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 3 3 6.0 1 4 8.0 4 8 16.0 3 11 22.0 3 14 28.0 19 33 66.0 9 42 84.0 2 44 88.0 6 50 100.0
Isepamicin Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 2 2 4.0 6 8 16.0 1 9 18.0 19 28 56.0 9 37 74.0 9 46 92.0 4 50 100.0
Amikacin Bacterial strain number accumulation bacterial strain number accumulation bacteriostasis rate (%) 2 2 4.0 2 4 8.0 4 8 16.0 12 20 40.0 15 35 70.0 5 40 80.0 4 44 88.0 3 47 94.0 3 50 100.0
Preliminary acute toxicity (the LD of SK-701 and SK-702 50) result of the test shows the LD of SK-701 and SK-702 50Close, be 50-75mg/Kg, in the scope of the clinical usage license of aminoglycoside antibiotics.
Can see that SK-701 and SK-702 have significant anti-MRSA and MRCNS activity, LD 50Therefore the result can be used for making each to the medicative medicament of drug-fast bacteria infection in the scope of aminoglycoside antibiotics clinical practice permission.
Synthetic method 1
R=CH 3CO, (S)-CH 2(NH 2) CH (OH) CO (AHP) or (S)-CH 2(NH 2) CH 2CH (OH) CO (AHB) R1=H or CH3
Synthetic method 2
R=CH 3CO, (S)-CH 2(NH 2) CH (OH) CO (AHP), (S)-CH 2(NH 2) CH 2CH (OH) CO (AHB) R1=H or CH 3
Synthetic method 3
Figure A20071013285600201
R=CH 3CO, (S)-CH 2(NH 2) CH (OH) CO (AHP), (S)-CH 2(NH 2) CH 2CH (OH) CO (AHB) R 1=H or CH 3
The present invention carries out the modification of target side chain for specificity in the 1-N position, adopts formoxyl protection intermediate, and the donor of formoxyl is a 2-formyl thyroidan, and its structural formula is as follows:
Figure A20071013285600202
The present invention is when being used for these derivants preparation drug-fast bacteria infection treated effective Pharmaceutical composition, be neutralized into salt soluble in water with acid earlier, wherein acid can be mineral acid example hydrochloric acid, phosphoric acid, sulphuric acid etc., also can be organic acid such as maleic acid, lactic acid, tartaric acid, the most frequently used be the sulfate made from sulphuric acid.
The preparation method of these pharmaceutical formulations disclosed by the invention, concrete method be with have 2 '-NH 2-3 ', the aminoglycoside antibiotics 1-N-acyl derivative of 4 '-two deoxidation architectural features or their pharmaceutical salts be as applicable carrier such as buffer agent, lubricant, disintegrating agent, binding agent, surfactant, antiseptic, sweeting agent, isotonic agent etc. on active component and the medicine; be that active component accounts for the ratio preparation that 0.01-99.99% and carrier account for 99.99-0.01% with the weight ratio, and form through encapsulation, sterilization.
The occupation mode of pharmaceutical formulation of the present invention, dosage are similar to other aminoglycoside antibiotics, and for example, the most frequently used application mode is an injection, and its dosage is 50-800mg/ days, divides 1-3 use.
The specific embodiment
Synthesizing of embodiment 1:1-N-(S)-3-amino-2-hydroxyl propionyl Gentamicin C1a
1) 3,2 ', 6 '-three-N-formoxyl Gentamicin C1a synthetic
25 gram Gentamicin C1as (GMC1a) stir dissolving down with 500mL dimethyl sulfoxine (DMSO), are cooled to room temperature, add 100mL dichloromethane, 32 gram four hydration cobalt acetates, at room temperature stirring and dissolving and complexations.Add 40 gram 2-formyl thyroidans in batches, stir reaction down 1 hour.500mL5 ℃ of cold water mix of adding is even in the reactant liquor, and separatory adds 5 gram active carbons and stirs filtration in 20 minutes in the liquid of upper strata, and filtrate extracts secondary with the dichloromethane extraction of 1/10 filtrate volume.
The upper strata water after washing eliminates DMSO, is used 0.4N ammonia eluting with 800mL HD-2 resin (ammonium type) post dynamic adsorption, begin fraction collection during to pH9.5, merge same composition, be concentrated into dried, with 100mL dissolve with methanol, evaporate to dryness dehydration, repeat once, obtain solid 20.5 grams.
Get above-mentioned solid 5 gram 200mL HD-2 resin column (height/diameter＞10) purification; with 0-0.4N ammonia gradient elution; the fraction collection eluent; merge same composition; be concentrated into dried; with the dehydration of dissolve with methanol, evaporate to dryness, repeat once, obtain solid product 3,2 ', 6 '-three-N-formoxyl Gentamicin C1a, 2.8 grams.[α] DT=154 °; Elementary analysis: C:44.32 H:7.41 O:12.35 (moisture: 5.6%, theoretical value: C:44.22 H:7.56 O:12.31).
2) 1-N-(S)-3-amino-2-hydroxyl propionyl Gentamicin C1a is synthetic
Solid 15 grams that obtain the above-mentioned first time are added in the 300mL methanol and dissolve, add 10.5 gram phthalyl amido-α-Qiang Jibingsuans (PHPA), 5 gram I-hydroxybenzotriazole monohydrate (HOBT) stirring and dissolving under the room temperature, add 8.4 gram dicyclohexylcarbodiimides (DCC) in batches, reacted 1 hour.
Reacting liquid filtering, filtrate decompression is concentrated into dried, adds 300mL ethanol, 80mL hydrazine hydrate, hydrazinolysis 6 hours.Reduction vaporization reclaims ethanol, is dissolved in water, and with the absorption of HD-2 resin column, purification, 0-0.4N ammonia eluting, fraction collection merges same composition, is concentrated into dried solid 7.2 grams that obtain.
Get above-mentioned solid 2 grams, use the 50mL water dissolution, microporous filter membrane (0.45 micron) filters, the filtrate lyophilization, and obtaining 1.7 gram solids is 1-N-(S)-3-amino-2-hydroxyl propionyl Gentamicin C1a alkali.
Other gets above-mentioned solid 5 grams and uses the 80mL water dissolution, adds 6N H 2SO 4Transfer pH4.5～7, add 2 gram activated carbon decolorizings, filter, the filtrate lyophilization obtains 7.1 gram 1-N-(S)-3-amino-2-hydroxyl propionyl Gentamicin C1a sulfate.
Embodiment 2:1-N-(S)-3-amino-2-hydroxyl propiono-3 " synthesizing of N-demethylation Gentamicin C1a
" N-demethylation Gentamicin C1a adds 20mL water, 100mL DMSO to 5 grams 3, and stirring and dissolving adds 10 gram zinc acetate stirring and dissolving, adds 8.5 gram 2-formyl thyroidan stirring reactions under the room temperature in batches.Reactant liquor adds 150mL cold water, and mix homogeneously filters.Filtrate begins fraction collection with acidulous cation resin D151 dynamic adsorption, washing back with 0.4N ammonia eluting during pH9.5, merge same composition, and reduction vaporization Wang Gan obtains solid 3.5 grams.
Above-mentioned solid is with step 2 among the embodiment 1) method carry out the 1-N acylation reaction and purification obtains 1-N-(S)-3-amino-2-hydroxyl propiono-3 " N-demethylation Gentamicin C1a alkali 1.8 grams.
Get the wherein above-mentioned solid of 1.5 grams 30mL water dissolution, 6N H 2SO 4Transfer pH4.5～7.0, add activated carbon decolorizing, filter, the filtrate lyophilization obtains 2.1 gram 1-N-(S)-3-amino-2-hydroxyl propiono-3 " N-demethylation Gentamicin C1a sulfate.
Embodiment 3:1-N-(S)-3-amino-2-hydroxyl propiono-3 " synthesizing of N-demethylation Gentamicin C1a
1-N-(S)-3-amino-2-hydroxyl propionyl Gentamicin C1a sulfate 8 grams add the 100mL water dissolution, add 10 gram sodium acetates, drip 10 gram iodine (dissolving of 100mL dimethyl formamide), 50～70 ℃ of stirring reactions 12 hours.The reactant liquor thin up is to 400mL, and with 100mL D151 resin dynamic adsorption, the washing back begins fraction collection with 0.4N ammonia eluting during pH9.5, merge same composition, and reduction vaporization is to doing.Add the 50mL water dissolution, with HD-2 (acidulous cation resin) resin column (height/diameter＞10) purification, 0-0.4N ammonia eluting, fraction collection.Merge same composition, be concentrated into driedly, use the 30mL water dissolution, add 6N H 2SO 4Transfer pH4.5～7, add 1 gram activated carbon decolorizing, filter, the filtrate lyophilization obtains 3.1 gram 1-N-(S)-3-amino-2-hydroxyl propiono-3 " N-demethylation Gentamicin C1a sulfate.
Embodiment 4. antibiotic aqueous injection
Prescription:
SK-701 10 grams
Anhydrous sodium sulfite 0.4 gram
Water for injection adds to 200 milliliters
pH 4.5～7.0
Technology: take by weighing main ingredient by prescription, be dissolved in the 160mL water for injection, adjust that to add active carbon behind the pH an amount of, add water to standardize solution 200mL, remove charcoal after the microporous filter membrane fine straining to clean, logical nitrogen embedding, 100 ℃ of flowing steam sterilizations 30 minutes.

Claims (10)

1. the application of aminoglycoside antibiotics in the Pharmaceutical composition of preparation treatment drug-fast bacteria infection, it is held and levies is that this aminoglycoside antibiotics has following 1-N acylated derivatives structure
Figure A2007101328560002C1
R=CH 3CO, (S)-CH 2(NH 2) CH (OH) CO, or (S)-CH 2(NH 2) CH 2CH (OH) CO, R 1=H or CH 3, R 2=H or CH 3
2. application as claimed in claim 1 is characterized in that this aminoglycoside antibiotics is R=(S)-CH 2(NH 2) CH (OH) CO, R 1=H, R 2=CH 3, structure is as follows:
Figure A2007101328560002C2
Be the application of 1-N-(s)-3-amino-2-hydroxyl propionyl gentamicinC la in the Pharmaceutical composition of preparation treatment drug-fast bacteria infection.
3. application as claimed in claim 1 is characterized in that this aminoglycoside antibiotics is R=(S)-CH 2(NH 2) CH (OH) CO, R 1=R 2=H, structure is as follows:
Figure A2007101328560002C3
" the application of N-demethylation gentamicinC la in the Pharmaceutical composition of preparation treatment drug-fast bacteria infection that be 1-N-(s)-3-amino-2-hydroxyl propionyl-3.
4. as the described application of claim 1-3, it is characterized in that described fastbacteria is a methicillin-resistant staphylococcus aureus.
5. as the described application of claim 1-3, it is characterized in that described fastbacteria is the methicillin-resistant coagulase negative staphylococcus.
6. as the described application of claim 1-3; described Pharmaceutical composition; it is characterized in that by forming, and be 0.01%～99.99% to be that 99.99%～0.01% weight proportion is formed with containing medicinal carrier by this 1-N acylated derivatives or its pharmaceutical salts as this 1-N acylated derivatives of active component or its pharmaceutical salts and pharmaceutical carrier.
7. as the preparation method of Pharmaceutical composition as described in the claim 6, it is characterized in that it being that 1-N acylated derivatives or its pharmaceutical salts with effective dose is mixed mutually with pharmaceutical carrier, make through the packing of routine, sterilization.
8. as Pharmaceutical composition as described in the claim 6, it is characterized in that being used to prepare the Pharmaceutical composition for the treatment of drug-fast bacteria infection is tablet, aqueous injection, injectable powder, collyrium, aerosol, cream or aerosol agent.
9. application as claimed in claim 1, the preparation method of described aminoglycoside antibiotics is characterized in that the preparation of following structural compounds
Figure A2007101328560003C1
R=CH 3CO, (S)-CH 2(NH 2) CH (OH) CO, or (S)-CH 2(NH 2) CH 2CH (OH) CO;
R 1=H or CH 3,
Comprise the steps:
1) carrying out formylation reaction after making parent nucleus compound 1 bit amino be complex state with bivalent metal ion, is zinc ion, cobalt ion or nickel ion as the bivalent metal ion of complexation;
2) remove metal ion;
3) carry out R base derivative reaction in the 1-N position;
4) specificity is removed the formylated protecting group;
5) target product is carried out purification, product purification adopts the cation exchange resin column chromatography method, carries out eluting with the ammonia spirit of variable concentrations; Or product purification employing adsorbent resin column chromatography method, carry out eluting with Different concentrations of alcohol, methanol or aqueous acetone solution.
10. application as claimed in claim 1, the preparation method of described aminoglycoside antibiotics is characterized in that the preparation of following structural compounds
Figure A2007101328560004C1
R=CH 3CO, (S)-CH 2(NH 2) CH (OH) CO, or (S)-CH 2(NH 2) CH 2CH (OH) CO,
R 1=H or CH 3,
Comprise the steps:
1) parent nucleus compound is realized 3 " obtaining 3 after the N demethylating reaction is also purified "-N-demethylation products with iodine or iodide;
2) carrying out formylation reaction after making 1 bit amino be complex state with bivalent metal ion, is zinc ion, cobalt ion or nickel ion as the bivalent metal ion of complexation;
3) remove metal ion;
4) carry out R base derivative reaction in the 1-N position;
5) specificity is removed the formylated protecting group;
6) target product is carried out purification, product purification adopts the cation exchange resin column chromatography method, carries out eluting with the ammonia spirit of variable concentrations; Or product purification employing adsorbent resin column chromatography method, carry out eluting with Different concentrations of alcohol, methanol or aqueous acetone solution.
CN2007101328564A 2007-10-09 2007-10-09 Application of aminoglycoside antibiotic in preparing pharmaceutical composition for treating drug-fast bacteria infection Active CN101152195B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2007101328564A CN101152195B (en) 2007-10-09 2007-10-09 Application of aminoglycoside antibiotic in preparing pharmaceutical composition for treating drug-fast bacteria infection
PCT/CN2008/001677 WO2009049490A1 (en) 2007-10-09 2008-09-28 Use of aminoglycoside antibiotic in the preparation of pharmaceutical composition for treating drug-resistant bacterial infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2007101328564A CN101152195B (en) 2007-10-09 2007-10-09 Application of aminoglycoside antibiotic in preparing pharmaceutical composition for treating drug-fast bacteria infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910165440A Division CN101723994A (en) 2007-10-09 2007-10-09 Method for preparing aminoglycoside antibiotic

Publications (2)

Publication Number Publication Date
CN101152195A true CN101152195A (en) 2008-04-02
CN101152195B CN101152195B (en) 2010-09-08

Family

ID=39254214

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007101328564A Active CN101152195B (en) 2007-10-09 2007-10-09 Application of aminoglycoside antibiotic in preparing pharmaceutical composition for treating drug-fast bacteria infection

Country Status (2)

Country Link
CN (1) CN101152195B (en)
WO (1) WO2009049490A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009049490A1 (en) * 2007-10-09 2009-04-23 Changzhou Fangyuan Pharmaceutical Co., Ltd. Use of aminoglycoside antibiotic in the preparation of pharmaceutical composition for treating drug-resistant bacterial infection
CN101928310A (en) * 2010-03-26 2010-12-29 常州方圆制药有限公司 3,2',6'-tri-N-acetyl gentamicin C1aprepn
CN102190690A (en) * 2011-04-01 2011-09-21 福州博立医药科技有限公司 Convenient high-yield Arbekacin synthesis method

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115838388A (en) * 2022-12-16 2023-03-24 无锡济煜山禾药业股份有限公司 Preparation method of 3-N-acetyl etimicin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1046512A (en) * 1974-03-19 1979-01-16 Peter J.L. Daniels Derivatives of diaminocyclitols and method for their preparation
US5900406A (en) * 1991-07-09 1999-05-04 Nzym, Inc. Use of antibiotics of the type 2-deoxystreptamine substituted with aminosugars to inhibit growth of microorganisms containing group I introns
CN101152195B (en) * 2007-10-09 2010-09-08 常州方圆制药有限公司 Application of aminoglycoside antibiotic in preparing pharmaceutical composition for treating drug-fast bacteria infection
CN101139371A (en) * 2007-10-09 2008-03-12 无锡苏科生物科技有限公司 Aminoglycoside antibiotics

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009049490A1 (en) * 2007-10-09 2009-04-23 Changzhou Fangyuan Pharmaceutical Co., Ltd. Use of aminoglycoside antibiotic in the preparation of pharmaceutical composition for treating drug-resistant bacterial infection
CN101928310A (en) * 2010-03-26 2010-12-29 常州方圆制药有限公司 3,2',6'-tri-N-acetyl gentamicin C1aprepn
CN101928310B (en) * 2010-03-26 2012-09-05 常州方圆制药有限公司 3,2',6'-tri-N-acetyl gentamicin C1aprepn
CN102190690A (en) * 2011-04-01 2011-09-21 福州博立医药科技有限公司 Convenient high-yield Arbekacin synthesis method
CN102190690B (en) * 2011-04-01 2015-01-21 福州博立医药科技有限公司 Convenient high-yield Arbekacin synthesis method

Also Published As

Publication number Publication date
WO2009049490A1 (en) 2009-04-23
CN101152195B (en) 2010-09-08

Similar Documents

Publication Publication Date Title
EP2125850B1 (en) Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof
TWI270575B (en) Process of purifying vancomycin hydrochloride
US4085208A (en) Process for preparing 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and novel 1-epimers and 1-N-alkyl derivatives produced thereby; methods for the use of the 1-epimer derivatives as antibacterial agents and compositions useful therefor
US4049796A (en) Amino glycoside antibiotics having antibacterial activity
PL105730B1 (en) METHOD OF MAKING NEW DERIVATIVES OF AMINOGLYCOSIDE ANTIBOTIC
CN101152195A (en) Application of aminoglycoside antibiotic in preparing pharmaceutical composition for treating drug-fast bacteria infection
JP2006519246A (en) High purity fondaparinux sodium pharmaceutical composition
DE2437160C3 (en) 1-N-ethylsisomicin and salts, processes for their preparation and pharmaceutical preparations containing these compounds
JPS6133039B2 (en)
CN101723994A (en) Method for preparing aminoglycoside antibiotic
CN101139371A (en) Aminoglycoside antibiotics
DE2724597C3 (en) 3&#39;-Deoxykanamycin C and 3 \ 4&#39;-Dideoxykanamycin C, their salts, processes for their preparation and antibacterial agents containing these compounds
DE2364999A1 (en) METHOD FOR DEHYDROXYLATION OF AMINOGLYCOSIDE ANTIBIOTICS
CA1111028A (en) N-benzyl anthracyclines
DE2612287A1 (en) AMINOGLYCOSIDE ANTIBIOTICS, THE METHOD OF MANUFACTURING THEM AND MEDICINAL PREPARATIONS CONTAINING THEM
US4066752A (en) 1-Desamino-1-hydroxy and 1-desamino-1-epi-hydroxy-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols; 1-desamino-1-oxo-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols, intermediates and use as antibacterial agents
US4140849A (en) Kanamycin C derivatives
DE2514985A1 (en) METHOD FOR MANUFACTURING DESOXYAMINOGLYCOSIDE ANTIBIOTICS
JP2016515589A5 (en)
WO2009152202A2 (en) New aminoglycosides: synthesis and use as antifungals
Boxler et al. Semisynthetic aminoglycoside antibacterials. Part 9. Synthesis of novel 1-and 3-substituted and 1-and 3-epi-substituted derivatives of sisomicin and gentamicin from the 1-and 3-oxo-derivatives
US4302449A (en) Carminomycin analogue
CA1081693A (en) Kanamycin c derivatives
Malabarba et al. Synthesis and biological evaluation of de (acetylglucosaminyl) didehydrodeoxy derivatives of teicoplanin antibiotics
KR20040071683A (en) Acarbose purification process

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: NONE WUXI SUKE BIO-TECHNOLOGY CO., LTD.

Effective date: 20081010

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20081010

Address after: Jiangsu city of Changzhou province Hehai Road 108 North, post encoding: 213022

Applicant after: Fangyuan Pharmaceutical Co., Ltd., Changzhou

Address before: Jiangsu District, Wuxi, Wuxi Road, Xintai Road, 8 (long Jiangnan intersection), Wuxi Overseas Students Pioneer Park B District comprehensive building, zip code: 214028

Applicant before: Wuxi Suke Biological Technology Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Application of aminoglycoside antibiotic in preparing pharmaceutical composition for treating drug-fast bacteria infection

Effective date of registration: 20131104

Granted publication date: 20100908

Pledgee: China honour financing Company limited by guarantee

Pledgor: Fangyuan Pharmaceutical Co., Ltd., Changzhou

Registration number: 2013990000816

PLDC Enforcement, change and cancellation of contracts on pledge of patent right or utility model
PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20190821

Granted publication date: 20100908

Pledgee: China honour financing Company limited by guarantee

Pledgor: Fangyuan Pharmaceutical Co., Ltd., Changzhou

Registration number: 2013990000816